Navepegritide

DRUG2 trials

Sponsors

Ascendis Pharma A/S

Conditions

Achondroplasia

Phase 2

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

RecruitingNCT06079398

Ascendis Pharma A/SAchondroplasia

Start: 2024-01-23End: 2028-12-01Target: 72Updated: 2026-04-08

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

RecruitingNCT06732895

Ascendis Pharma A/SAchondroplasia

Start: 2024-12-10End: 2027-09-01Target: 24Updated: 2026-04-21